上海2026年8月19日 /美通社/ -- 雲頂新耀（HKEX 1952.HK）是一家專註於創新葯研發、臨床開發、製造及商業化的生物製藥公司，今日公布2026年度中期業績報告（截至2026年6月30日）及業務進展。

2026年上半年，雲頂新耀實現強勁增長，並取得盈利的重要里程碑。公司總收入達人民幣11.48億元，同比增長157%。報告期內，剔除非現金項目后毛利率達73.7%。公司非國際財務報告準則下實現凈利潤人民幣9,723萬元，國際財務報告準則下凈虧損同比收窄98%；運營費用占收入比重同比下降64.0個百分點，反映公司運營效率和執行效率的持續提升。

截至2026年6月30日，公司現金儲備充裕，達人民幣18.59億元；報告期后，公司於2026年7月收到希布替尼（EVER001）全球授權許可及合作協議項下的人民幣7.7億元首付款，現金餘額進一步充實，為公司後續研發投入及業務拓展提供有力支持。

雲頂新耀董事會主席吳以芳表示：「2026年上半年，雲頂新耀正式邁入3.0階段，成為創新驅動的綜合性生物製藥公司。在2030戰略指導下，公司持續提升創新資源整合能力、商業化運營能力和全球化發展能力，加速創新價值釋放，為長期高質量發展奠定更加堅實的基礎。

上半年，公司經營質量持續提升，實現扭虧為盈；創新產品管線不斷豐富，研發成果持續積累，臨床價值進一步提升。同時，公司持續強化『雙向』BD能力，一方面積極推動創新資產的全球合作與價值變現，成功完成首款擁有全球權益產品希布替尼（EVER001）的對外授權；另一方面，聚焦核心治療領域，持續引進具有較高商業化確定性和同類最佳潛力的中後期創新資產。通過BD合作、戰略投資、併購整合及本地化製造等方式，公司持續提升創新資源配置效率，加快推動創新成果向臨床價值和商業價值轉化。

公司持續構建具有全球競爭力的創新產品組合，並不斷提升商業化、研發註冊、供應鏈與製造等核心能力，並依託持續升級、升維的『A2MS』商業化運營體系，進一步增強商業化運營能力。與此同時，公司持續深化全球化布局，完成對海森生物製藥（新加坡）有限公司的收購，拓展亞太商業化布局，提升公司的國際競爭力和長期增長潛力。

公司始終堅持可持續發展理念，重視長期價值創造，持續強化治理與風險管理，以穩健經營夯實長期發展基礎。康橋資本及公司董事持續增持公司股份，體現了對公司戰略方向和長期發展前景的堅定信心。

雲頂新耀將繼續推進2030戰略，堅持創新驅動發展，持續創造長期價值，不斷提升競爭力，成為一家『值錢、值得期待、值得信任』的公司。」

雲頂新耀首席執行官羅永慶表示：「2026年上半年，公司圍繞既定戰略，加快推動創新成果轉化，商業化、BD、自主研發和全球化布局協同推進，經營質量持續改善，增長動能進一步增強。

商業化方面，公司核心產品持續釋放增長潛力，耐賦康^®銷售收入保持強勁增長，維適平^®獲批后快速實現商業化落地，依嘉^®院端銷量保持穩健增長。海森生物商業化服務合作穩步推進，持續貢獻收入。依託『A2MS』商業化運營體系及精益管理體系，公司持續提升市場覆蓋和運營效率，推動創新產品與成熟產品協同增長。

在BD和自主研發方面，公司持續推進創新資產的全球合作與優質創新資產引進，自主研發及創新技術平台也持續取得臨床進展，進一步豐富未來增長動力。與此同時，隨着泛亞太商業化平台的建立，公司進一步將中國市場驗證的商業化能力複製至亞洲市場，推動現有及未來產品拓展亞洲市場。

這些進展進一步夯實了公司的增長基礎。展望未來，公司將繼續以全球創新資源整合和全價值鏈運營能力建設為重點，持續提升執行效率和全球競爭力，加快創新成果轉化和價值釋放，為實現2030戰略目標奠定更加堅實的基礎。」

商業化方面，公司核心產品持續釋放增長潛力。耐賦康^®銷售收入保持強勁增長，公司持續深耕核心醫院網絡，拓展非核心市場覆蓋，加強醫生及患者教育，積累真實世界證據，推動「對因治療、儘早治療、長期治療」診療策略加速落地。維適平^®獲批后快速實現商業化落地，本地化生產建設持續推進。依嘉^®院端銷量保持穩健增長，本地化生產有序開展。與此同時，海森生物商業化服務合作穩步推進，貢獻銷售收入。公司與海南合瑞就耐賦康^®相關專利達成諒解，並開展布地奈德腸溶膠囊商業化合作，進一步拓展患者的用藥選擇。

在BD合作方面，公司持續推進創新資產的全球價值釋放與優質創新資產引進。對外授權方面，公司與Travere Therapeutics就希布替尼（EVER001）達成獨家授權許可與合作協議，並與合作夥伴共同推進其全球開發及商業化，實現自主研發創新資產的全球價值變現。對內引進方面，公司聚焦核心治療領域和中後期資產，持續完善產品組合：在腎科及自身免疫領域引入MT1013、DMX-200和倍捷欣^®；心血管領域引入星必妥^®和維卡格雷，進一步完善心血管產品組合；在眼科領域引入LNZ100，與VIS-101共同強化眼科布局。隨着多項資產進入關鍵註冊及商業化階段，公司未來產品增長梯隊進一步清晰，其中，星必妥^®預計2026年第三季度獲批上市，樂瑞泊^®和LNZ100預計於2027年獲批上市，MT1013有望於2028年獲批上市。

研發方面，公司自主創新能力持續轉發為臨床開發進展。希布替尼52周Ib/IIa期臨床研究取得積極結果，並在中國啟動II期籃式試驗，進一步探索其在FSGS、MCD和IgAN等自身免疫性腎臟疾病中的治療潛力。與此同時，自研AI+mRNA平台持續取得突破，EVM16完成首次人體臨床數據讀出，並計劃於2026年第四季度啟動IIT Ib期臨床研究；自體生成CAR-T療法EVM18已啟動針對多類自身免疫疾病的IIT研究，並穩步推進全球IND申報。

全球化布局方面，公司完成對海森生物製藥（新加坡）的收購，獲得泛亞太商業化平台，加快將中國市場驗證的商業化能力複製至亞洲市場，推動現有及未來產品拓展亞洲市場，進一步提升全球商業化能力。

關於雲頂新耀
雲頂新耀是一家專註於創新葯研發、臨床開發、製造和商業化的生物製藥公司，致力於滿足全球市場尚未滿足的醫療需求。雲頂新耀的管理團隊在中國及全球領先製藥企業擁有深厚的專長和豐富的經驗。公司在浙江嘉善擁有具備商業化規模的全球生產基地，並依據中國、美國及歐盟標準建立了完善的GMP生產質量管理體系。

公司聚焦自身免疫、眼科、急重症及CKM（心血管、腎臟及代謝）等疾病治療領域，已打造集全渠道商業化體系與藥品全生命周期商業化能力於一體的商業化平台，並以擁有全球權益的自研mRNA平台為基礎，持續推進mRNA in vivo CAR-T與mRNA腫瘤疫苗等現有管線，同時通過引進及生態孵化潛力平台，拓展研發能力，同時強化全球化布局，加快國際化發展進程。更多信息，請訪問公司官網：www.everestmedicines.com。

前瞻性聲明：
本新聞稿所發布的信息中可能會包含某些前瞻性表述，乃基於本公司或管理層在做出表述時對公司業務運營情況及財務狀況的現有看法、相信、和現有預期，可能會使用「將」、「預期」、「預測」、「期望」、「打算」、「計劃」、「相信」、「預估」、「確信」及其他類似詞語進行表述。這些前瞻性表述並非對未來業績的保證，會受到風險、不確定性及其他因素的影響，有些乃超出本公司的控制範圍，難以預計。因此，受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展等各種因素及假設的影響，實際結果可能會與前瞻性表述所含資料有較大差別。本公司及各附屬公司、各位董事、管理人員、顧問及代理未曾且概不承擔更新該稿件所載前瞻性表述以反映在本新聞稿發布日後最新信息、未來項目或情形的任何義務，除非法律要求。

SHANGHAI, Aug. 19, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced its interim results for the first half of 2026 along with a corporate update.

Everest delivered strong growth and reached an important profitability milestone in the first half of 2026. Total revenue increased 157.3% year-on-year to RMB 1,147.8 million, driven by continued commercial momentum across the Company's portfolio. Gross margin excluding non-cash items reached 73.7%, while operating expenses as a percentage of revenue decreased by 64.0 percentage points year-on-year, reflecting increasing operating leverage and execution efficiency.

The Company achieved non-IFRS net profit of RMB 97.2 million, while IFRS net loss narrowed by 98% year-on-year. Everest ended the period with RMB 1,858.8 million in cash. Following the reporting period, the Company received approximately RMB 770 million in July from the upfront payment under its global licensing and collaboration agreement for civorebrutinib, further strengthening its financial position and capacity to invest in future growth.

Mr. Yifang Wu, Chairman of the Board of Everest Medicines, said:

"Everest Medicines has entered a new phase of development as an innovation-driven, integrated biopharmaceutical company. Guided by our 2030 Strategy, we are strengthening our capabilities in innovation, commercialization, and global development, accelerating the realization of global value and laying a stronger foundation for sustainable, high-quality growth.

During the period, the Company achieved profitability, while expanding our innovative pipeline and advancing our R&D programs. We continued to strengthen our BD capabilities through global partnerships for our innovative assets and selective in-licensing of mid- to late-stage innovative assets with strong commercial potential and best-in-class potential across our core therapeutic areas. These efforts, together with strategic investments, M&A, and localized manufacturing, are enhancing the efficiency of innovation resource allocation and accelerating the translation of innovation into clinical and commercial value.

The Company remains focused on building a globally competitive innovative product portfolio and strengthening capabilities across commercialization, R&D and regulatory affairs, supply chain, and manufacturing. We are also deepening our global footprint and further enhancing our commercialization capabilities. Sustainable development and long-term value creation remain central to our approach, with continued focus on governance and risk management. Continued share purchases by CBC Group and the Company's Directors demonstrate their strong confidence in our strategic direction and long-term prospects.

As we execute our 2030 Strategy, we will pursue innovation-driven growth, create long-term value, and enhance our competitiveness, to build Everest into a leading biopharmaceutical company with long-term, sustainable value creation."

Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, said:

"In the first half of 2026, the Company continued to execute its strategy and accelerate the translation of innovation into clinical and commercial value. Solid progress across commercialization, BD, in-house R&D, and global expansion further strengthened our foundation for sustainable growth and our ability to bring innovative therapies to patients.

Commercially, our marketed portfolio continued to gain momentum, led by strong growth from NEFECON®, while VELSIPITY® advanced rapidly following approval and XERAVA® delivered steady hospital sales growth. Leveraging our 'A2MS' commercial operating system and lean management approach, we continued to improve execution efficiency and expand market access across both innovative and established products. Meanwhile, our BD strategy is building a diversified portfolio of future growth drivers through global partnerships for internally developed assets and selective in-licensing of differentiated innovative assets, while our in-house R&D continues to generate clinical progress.

With the establishment of a pan-Asia-Pacific commercialization platform, we are also extending our proven capabilities from China into other Asian markets. Looking ahead, Everest Medicines will integrate global innovation resources with end-to-end operating capabilities, strengthen execution across the value chain, and accelerate the translation of innovation into value as we advance our 2030 Strategy."

During the first half of 2026, the Company continued to expand the value of its marketed portfolio. NEFECON® maintained strong sales momentum, supported by deeper penetration across key hospitals, broader market expansion, enhanced physician and patient education, and continued generation of real-world evidence to support broader adoption of treatment strategies focused on addressing underlying causes, early intervention, and long-term management.

Following approval, VELSIPITY® moved rapidly into commercialization, with local manufacturing progressing. XERAVA® delivered steady hospital sales growth, while local manufacturing advanced as planned. Meanwhile, commercialization services for Hasten Biopharmaceuticals continued to contribute to revenue growth.

The Company also reached an understanding with Hainan Herui Pharmaceutical Co., Ltd. regarding certain NEFECON®-related patent matters and entered into a commercialization collaboration for budesonide enteric capsules, further broadening treatment options for patients. Leveraging its "A2MS" commercial operating system and lean management approach, the Company continued to enhance execution efficiency, expand market access, and drive growth across both innovative and established products.

The Company continued to strengthen its BD capabilities through global partnerships for internally developed assets and selective in-licensing of differentiated innovative assets across its core therapeutic areas. Through the exclusive licensing and collaboration agreement with Travere Therapeutics for civorebrutinib, the Company is working with its partner to advance its global development and commercialization, realizing the global value of the innovative asset.

At the same time, the Company continued to selectively introduce mid- to late-stage assets with strong commercial potential. MT1013, DMX-200, and Bejescin® strengthened its nephrology and autoimmune portfolio; CARDAMYST® and Sumecigrel (formerly known as Vicagrel) further expanded its cardiovascular portfolio; and LNZ100, together with VIS-101, enhanced its ophthalmology portfolio.

With multiple assets moving through key regulatory and commercialization milestones, the Company is building a diversified portfolio of future growth drivers. CARDAMYST® is expected to receive approval in the third quarter of 2026, LEROCHOL® and LNZ100 are expected to receive approval in 2027, and MT1013 is expected to receive approval in 2028.

The Company's in-house R&D also translated into clinical progress. Civorebrutinib achieved positive 52-week Phase 1b/2a clinical results, and a Phase 2 basket trial has been initiated in China to further evaluate its potential in autoimmune kidney diseases, including FSGS, MCD, and IgAN.

The Company's proprietary AI+mRNA platform also advanced, with EVM16 achieving its first-in-human clinical data readout and planned to enter an investigator-initiated Phase 1b study in the fourth quarter of 2026. EVM18, the Company's in vivo CAR-T therapy, has initiated IIT studies across multiple autoimmune diseases and is advancing toward global IND filings.

The acquisition of Hasten Biopharmaceuticals (SG) Pte. Ltd. further strengthened the Company's global commercialization capabilities and established a pan-Asia-Pacific commercialization platform. The platform provides a foundation for scaling the Company's proven commercialization capabilities from China across Asian markets, supporting the regional expansion of both existing and future products.

Through continued investment in innovation, commercialization, global development, and end-to-end capabilities, Everest Medicines is strengthening the foundation for sustainable long-term growth and supporting the execution of its 2030 Strategy.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. The Company's therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com. 

Forward-Looking Statements:

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

Corporate Health Management Business Grows Steadily; AI Healthcare Empowerment Drives Continued Profitability Improvement

HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor" or the "Company"; Stock Code: 1833.HK) announced its interim results for the six months ended June 30, 2026. During the period, the Company continued to improve its business quality and steadily enhance profitability. As the core flagship of Ping An Group's health and senior care ecosystem, the Company continued to deepen its managed care model with Chinese characteristics. It continued to upgrade its "online, in-hospital, at-home, and corporate" service network and empower full-scenario services through medical AI, providing users with one-stop medical, health, and senior care solutions that are worry-free, time-saving, and money-saving.

During the period, the Company recorded total revenue of RMB2.48 billion; profit attributable to owners of the parent of RMB219.3 million, up 63.5% year on year; and adjusted net profit of RMB226.8 million, up 37.7% year on year. Meanwhile, the Company's core businesses maintained steady growth momentum, with continued improvement in operating quality, further optimizing its revenue mix. Revenue from the commercial insurance enablement business (F-end), reached RMB1.58 billion; the corporate health management business (B-end) maintained high growth, with revenue reaching RMB713.8 million, representing a significant year-on-year increase of 65.1% and accounting for 28.7% of total revenue, up 11.5 percentage points year on year.

On the same day, as reviewed and approved by the Board, Mr. Zhu Yougang was appointed as Chairman of the Board and Non-executive Director. Mr. Zhu joined Ping An Group in 1994 and currently serves as Secretary of the Party Committee, Chairman, and Chief Executive Officer of Ping An Health Insurance, as well as Secretary of the Party Committee and Chairman of Peking University Medical Management Co., Ltd. The Board stated that it remains highly optimistic about the development opportunities of "medical-insurance synergy". Going forward, the Company will focus on building an integrated online-to-offline healthcare ecosystem, providing users with one-stop, full-lifecycle medical, health and elder-care services.

Deepening the China style HMO Model, Core Businesses Developing Steadily

As China's population ages, demand for senior care, healthcare and related services is shifting from discretionary spending to a basic necessity. During the period, the Company deeply integrated its medical service capabilities with Ping An Group's payment strengths in financial services and insurance, establishing a tiered and classified health benefits system that integrates insurance and health care. For customers with wealth-management insurance products, the Company collaborated with Ping An Life Insurance to launch the "Medical Visit Access" health service plan, providing customers with cutting-edge diagnostics and full-process medical care resources. For high-net-worth customers, the Company launched the new "Private Membership Club", integrating premium medical resources such as cutting-edge diagnostics (e.g. tumor genetic testing and PET/MR imaging) and advanced therapies. For pension insurance customers, the Company upgraded its home-based senior care service system, partnering with Ping An Life Insurance to launch the dedicated "Ping An Home" service brand, promoting a shift from reactive response to proactive health management. As of the end of the reporting period, the average first-year premium per new life policy of Ping An Home customers increased 9.7 times. The number of customers eligible for home-based senior care services exceeded 310,000, while the services covered 140 cities nationwide.

The corporate health management business (B-end) continued to demonstrate strong momentum. Over the past 12 months, the Company served more than 7,700 paying corporate clients, representing a year-on-year increase of more than 73%. The business focuses on large and medium-sized enterprises, supported by dedicated account service teams. At the product level, the Company worked with Ping An Group to build an integrated solution combining "commercial insurance + health insurance plans + health care services," comprehensively covering diverse workplace health needs. At the operations level, the Company provided enterprise-specific solutions by assigning dedicated service teams to key corporate clients and customizing benefits for their employees. At the same time, the Company actively developed its offline three-kilometer service network, "Ping An Circle." As of the end of the period, more than 500 sites had been established, integrating high-quality medical resources to provide corporate employees with one-stop services such as health consultations, health checkup report interpretation, chronic disease management, and medication guidance. The company is also expanding its "Ping An Health Pay" one-stop settlement network. More than 1,800 corporate clients, covering over 1 million employees, now have access to the service, which enables efficient medical-bill settlement without upfront payments or in-person paperwork.

Continuously Strengthening the "Online, In-hospital, At-home, and Corporate" Service Network to Consolidate Barriers in the Medical, Health, and Senior Care Ecosystem

During the reporting period, the Company continued to enhance its "online, in-hospital, in-home, and in-company" service system to meet demand for online consultation, workplace health coverage and home-based senior care. The initiative integrates online and offline services and strengthens the company's capabilities in providing health management across the full life cycle.

Online services, the Company continuously upgraded its multi-tiered family doctor service system to provide policyholders and corporate employees with full-cycle, proactive medical and health management services. The "AI + Physician" service achieved 100% coverage among Ping An Group's retail customers. During the period, AI Doctor was used by over 9.7 million users. For users with chronic conditions, the Company launched the "integrated comorbidity management" service, providing refined and dynamic health interventions and driving the transformation of medical services from reactive consultation to proactive health management.

In-hospital services, the Company continued to expand its high-quality offline medical resources, partnering with 3,216 Ping An Selected Hospitals, including 1,732 3A hospitals. It built a team of approximately 50,000 in-house and contracted external doctors, with over 3,700 contracted expert doctors. "Ping An Health Pay" has covered 149 thousand of the nearly 245 thousand partner pharmacies nationwide, connecting in-hospital and out-of-hospital medical settlement channels and simplifying the process of medical visits and medication purchases for users.

At-home services, the Company collaborated with Ping An Life Insurance to upgrade and launch the "Ping An Home" service brand, with home-based senior care services expanded to 140 cities nationwide.

Corporate services, the Company rolled out high-quality workplace health management pilots across multiple regions in China, building the "1124" corporate health-management framework tailored to employers' needs. The model comprises one on-site corporate clinic, a dedicated team of company-service specialists and four categories of integrated medical and health services.

The Company, as a core member of the drafting team, was also deeply engaged in the entire formulation process of the first domestic association standard document for longevity medicine-based geriatric health service, helping to fill the gap in standardized longevity medicine service in China and upgrade home-based senior care and medical services through a standardized framework.

Bolstering AI Capabilities and Applications, "Data + Model + real-world Scenarios" Drives Gross Profit Growth

In 2026, China introduced supportive policies to accelerate the large-scale rollout of AI in healthcare. Building digital health, smart medical services and AI-assisted diagnosis and treatment is a key part of implementing the Healthy China 2030 strategy. Leveraging its massive medical data accumulated over the years, the Company continued to strengthen its "data + model + real-world scenarios" closed-loop capabilities, iteratively upgraded its large medical model Ping An Medical Master® and refined five dedicated models for key vertical medical fields. During the period, AI business contributed approximately 4.6% of the Company's gross profit.

In serious medical scenarios, the Company built differentiated strengths through the "AI + Physician" model. This system has been fully integrated into all applications within Ping An Group's app matrix, achieving 100% coverage of the Group's retail customers. Currently, AI Doctor can precisely diagnose more than 11.3 thousand diseases, with an accuracy rate of nearly 96% in AI Doctor-aided diagnosis/treatment. The AI-enabled MDT platform has achieved an accuracy rate of nearly 90% in diagnosing complex diseases and formulating treatment plans. In addition, the Company further upgraded its AI-enabled MDT assistance platform for complex disease diagnosis, expanding from its original application in breast cancer to gastric cancer.

Ping An Good Doctor stated that the Company will continue to seize greater development opportunities in the medical and health industry. Taking advantage of Ping An's service-year initiatives, the Company will uphold its commitment to inclusive services for the public, and continue to provide users with high-quality medical, health, and senior care services that are worry-free, time-saving, and money-saving, while creating sustainable value returns for shareholders.

10.5 Billion Parcels Expanded Market Share to 19.9%
Adjusted Net Income Increased 50.3% to RMB3.1 Billion

SHANGHAI, Aug. 19, 2026 /PRNewswire/ -- ZTO Express (Cayman) Inc. (NYSE: ZTO and SEHK: 2057), a leading and fast-growing express delivery company in China ("ZTO" or the "Company"), today announced its unaudited financial results for the second Quarter ended June 30, 2026^[1]. The Company grew parcel volume by 6.5% year over year while maintaining high quality of service and customer satisfaction. Adjusted net income increased 50.3%^[2] to RMB3.1 billion. Net cash generated from operating activities was RMB4.6 billion.

Second Quarter 2026 Financial Highlights

• Revenues were RMB14,549.9 million (US$2,144.4 million), an increase of 23.0% from RMB11,831.8 million in the same period of 2025.
• Gross profit was RMB3,733.3 million (US$550.2 million), an increase of 26.8% from RMB2,944.4 million in the same period of 2025.
• Net income was RMB3,077.6 million (US$453.6 million), an increase of 56.7% from RMB1,964.6 million in the same period of 2025.
• Adjusted EBITDA^[3] was RMB4,241.4 million (US$625.1 million), an increase of 20.0% from RMB3,534.9 million in the same period of 2025.
• Adjusted net income was RMB3,086.1 million (US$454.8 million), an increase of 50.3% from RMB2,052.7 million in the same period of 2025.
• Basic and diluted net earnings per American depositary share ("ADS"^[4]) were RMB3.99 (US$0.59) and RMB3.78 (US$0.56), an increase of 64.9% and 59.5% from RMB2.42 and RMB2.37 in the same period of 2025, respectively.
• Adjusted basic and diluted earnings per American depositary share attributable to ordinary shareholders^[5] were RMB4.00 (US$0.59) and RMB3.79 (US$0.56), an increase of 58.1% and 52.8% from RMB2.53 and RMB2.48 in the same period of 2025 respectively.
• Net cash provided by operating activities was RMB4,563.6 million (US$672.6 million), compared with RMB2,168.2 million in the same period of 2025.

Operational Highlights for Second Quarter 2026

• Parcel volume was 10,486 million, increased 6.5% from 9,847 million in the same period of 2025.
• Number of pickup/delivery outlets was over 31,000 as of June 30, 2026.
• Number of direct network partners was approximately 6,000 as of June 30, 2026.
• Number of self-owned line-haul vehicles was over 10,000 as of June 30, 2026.
• Number of line-haul routes between sorting hubs was over 3,600 as of June 30, 2026.
• Number of sorting hubs was 92 as of June 30, 2026, among which 87 are operated by the Company and 5 by the Company's network partners.

Mr. Meisong Lai, Founder, Chairman and Chief Executive Officer of ZTO, commented, "In the second quarter of 2026, ZTO remained focused on elevating service quality and customer experience, improving operational efficiency, and fostering fair, transparent network policies. We handled a total parcel volume of 10.5 billion, representing a 6.5% year–over–year increase, outpacing the industry average by 2.3 percentage points. Adjusted net income reached RMB 3.1 billion. Daily average retail parcel volume continued to grow faster than traditional e–commerce parcel volumes. This structural shift boosted parcel volumes while enhancing overall profit margins."

Mr. Lai added, "China's express–delivery industry continued to benefit from regulatory guidance, with broad–based profit expansion marking a shift in priorities toward value–driven development alongside volume growth. ZTO's Quality–First commitment and consistent performance are backed by our industry–leading operational efficiency and fairness–oriented network governance. Deep–rooted in our Shared–Success philosophy and practices, we enable and support improved returns for our network partners and couriers, while delivering sound profitability for the company. Supported by constructive regulatory guidance and our competitive advantages — including advancing digital–technology capabilities and nurtured trust and cohesiveness across our franchise partner network — we are well positioned to navigate industry and economic cycles."

Ms. Huiping Yan, Chief Financial Officer of ZTO, commented, "For the second quarter this year, our core express ASP rose 15.5% in the second quarter, supported by an improved revenue mix driven by higher–value key–account volumes, including rapidly expanding reverse–logistics business. Despite cost pressures stemming from oil–price volatility, combined unit sorting and transportation costs decreased by 2 cents, thanks to digitization and lean operations. SG&A, excluding SBC, represented approximately 3.8% of revenue, compared with 5.2% in the same period last year. Operating cash flow was RMB 4.6 billion, while capital expenditure totaled RMB 952 million."

Ms. Yan added, "ZTO's long–standing profitable–growth strategy remains effective amid today's subdued growth environment. Our steady market–share gains are bolstered by sustained government efforts against involution, as well as our ongoing focus on the stability of our unique franchise–partner network, which thrives on the equitable allocation of risks and rewards. We intend to further solidify our volume leadership. Considering evolving market dynamics and slowing industry parcel–volume growth for the full year, we have updated our annual parcel–volume growth guidance to 6–10% year–over–year."

Total Revenues were RMB 14,549.9 million (US$ 2,144.4 million), increased 23.0% from RMB11,831.8 million in the same period of 2025. Revenue from the core express delivery business increased by 23.0% compared to the same period of 2025 as a result of a 6.5% growth in parcel volume and a 15.5% increase in parcel unit price. Within core express delivery revenue, key account revenue, generated by direct sales organizations, increased by 63.6% mainly driven by increase in e-commerce return parcels. Revenue from freight forwarding services increased by 21.1% compared to the same period of 2025. Revenue from sales of accessories, largely consisted of sales of thermal paper for digital waybills, decreased by 1.7%. Other revenues were mainly derived from financing services.

Total cost of revenues was RMB10,816.6 million (US$1,594.2 million), an increase of 21.7% from RMB8,887.4 million in the same period last year.

Line-haul transportation cost was RMB3,375.6 million (US$497.5 million), increased 2.6% from RMB3,290.9 million in the same period last year. The unit transportation cost decreased 3.0% or 1 cent mainly attributable to better economies of scale and improved load rate through more effective route planning offsetting higher diesel prices.

Sorting hub operating cost was RMB2,505.8 million (US$369.3 million), increased 3.8% from RMB2,414.8 million in the same period last year. The increase primarily consisted of (i) RMB84.5 million (US$12.5 million) increase in labor-associated costs partially offset by automation-driven efficiency improvements, and (ii) RMB14.8 million (US$2.2 million) increase in depreciation and amortization costs associated with automation facilities and equipment upgrades. As of June 30, 2026, there were 782 sets of automated sorting equipment in service, compared to 690 sets as of June 30, 2025.

Cost of accessories sold was RMB145.8 million (US$21.5 million), decreased by 3.6% compared with RMB151.2 million in the same period last year.

Other costs were RMB4,609.7 million (US$679.4 million), increased 61.2% from RMB2,860.2 million in the same period last year, which was mainly due to an increase of RMB1,620.4 million (US$238.8 million) for pickup and dispatching costs paid to network partners associated with serving key account customers, primarily for handling e-commerce return parcels.

Gross Profit was RMB3,733.3 million (US$550.2 million), increased by 26.8% from RMB2,944.4 million in the same period last year. Gross margin rate improved to 25.7% from 24.9% in the same period last year.

Total Operating Expenses were RMB505.3 million (US$74.5 million), compared to RMB469.3 million in the same period last year.

Selling, general and administrative expenses were RMB556.7 million (US$82.0 million), decreased by 10.7% from RMB623.6 million in the same period last year, mainly due to a RMB 40.8 million (US$6.0 million) allowance of credit losses relating to financing receivables recognized in the same period of last year.

Other operating income, net was RMB51.3 million (US$7.6 million), compared to RMB154.3 million in the same period last year. Other operating income mainly consisted of (i) RMB23.7 million (US$3.5 million) of government subsidies and tax rebates, and (ii) RMB27.6 million (US$4.1 million) of rental and other income.

Income from operations was RMB3,227.9 million (US$475.7 million), increased 30.4% from RMB2,475.1 million for the same period last year. The operating margin rate increased to 22.2% from 20.9% in the same period last year.

Interest income was RMB155.7 million (US$22.9 million), compared with RMB208.7 million in the same period last year.

Interest expenses was RMB70.6 million (US$10.4 million), compared with RMB98.1 million in the same period last year.

Gain from fair value changes of financial instruments was RMB45.4 million (US$6.7 million), compared with a loss of RMB3.6 million in the same period last year. Such gain or loss from fair value changes of the financial instruments is quoted by commercial banks according to market-based estimation of future redemption prices.

Income tax expenses were RMB258.6 million (US$38.1 million) compared to RMB575.5 million in the same period last year. The overall income tax rate was 7.7%, down 15.2 percentage points year over year. The decline was mainly attributable to an income tax refund of RMB344.3 million (US$50.7 million) received by Shanghai Zhongtongji Network Technology Co., Ltd. (上海中通吉網絡技術有限公司), a wholly owned subsidiary of the Company, upon its recognition as a "Key Software Enterprise" qualifying for a preferential tax rate of 10% for tax year 2025.

Net income was RMB3,077.6 million (US$453.6 million), which increased by 56.7% increase from RMB1,964.6 million in the same period last year.

Basic and diluted earnings per ADS attributable to ordinary shareholders were RMB3.99 (US$0.59) and RMB3.78 (US$0.56), compared to basic and diluted earnings per ADS of RMB2.42 and RMB2.37 in the same period last year, respectively.

Adjusted basic and diluted earnings per ADS attributable to ordinary shareholders were RMB4.00 (US$0.59) and RMB3.79 (US$0.56), compared with RMB2.53 and RMB2.48 in the same period last year, respectively.

Adjusted net income was RMB3,086.1 million (US$454.8 million), compared with RMB2,052.7 million during the same period last year.

EBITDA^[1] was RMB4,231.3 million (US$623.6 million), compared with RMB3,446.8 million in the same period last year.

Adjusted EBITDA was RMB4,241.4 million (US$625.1 million), compared to RMB3,534.9 million in the same period last year.

Net cash provided by operating activities was RMB4,563.6 million (US$672.6 million), compared with RMB2,168.2 million in the same period last year.

Appointment of New Independent Director

The Board of Directors of the Company (the "Board") has announced that Mr. Wei Zhu has been appointed as an independent director, effective August 19, 2026.

Mr. Zhu has over 35 years of experience in management consulting, investment banking, private equity investment and large-scale corporate management. From April 2026, Mr. Zhu has served as a director and advisor to Shanghai Xforceplus Information Technology Co., Ltd. and its affiliate for AI technology. From June 2024 to February 2026, Mr. Zhu served as co-head of North Asia at Alvarez & Marsal. From 2018 to 2021, Mr. Zhu served as chairman of Greater China at Accenture plc and was appointed to Accenture's global management committee in 2020. Previously, Mr. Zhu served as global co-head of Standard Chartered Bank's private equity business from 2009 to 2017, senior managing director and head of CVC Capital Partners from 2008 to 2009, managing director at Goldman Sachs Gao Hua Securities Company Limited from 2005 to 2008, senior partner and president of Greater China at Roland Berger from 2004 to 2005, and president of Greater China at A.T. Kearney from 2001 to 2003. Mr. Zhu has served as an independent director of Shanghai Foreign Service Holding Group Co., Ltd. since September 2021. Mr. Zhu received a Bachelor in Foreign Service from Georgetown University in 1986 and an MBA from the University of Chicago in 1992.

Shareholder Return Update

As disclosed in March 2026, the Board has approved an enhanced return mechanism, pursuant to which the Company targets an aggregate annual shareholder return ratio of no less than 50% of its adjusted net income for the prior fiscal year, comprising both cash dividends and share repurchases.

As of the end of the second quarter, the Company had repurchased an aggregate of 31,788,692 Class A Ordinary Shares for US$740 million (including repurchase commissions) in 2026, equivalent to 52% of its adjusted net income for 2025. As such, the Board did not recommend the distribution of an interim dividend for the first half of 2026.

In March 2026, the Board also approved a new share repurchase program (the "New Program"), authorizing share repurchases of up to US$1.5 billion of its shares over a 24-month period, effective from March 20, 2026 to March 20, 2028. As of the end of the second quarter of 2026, the Company had repurchased an aggregate of 6,161,216 ADSs for US$138 million (including repurchase commissions) under the New Program, leaving US$1.36 billion of capacity under the authorisation.

Business Outlook

Based on current market and operating conditions, the Company revises its previously stated annual guidance. Parcel volume for 2026 is expected to increase by 6.0% to 10.0% year over year, representing a parcel volume range of 40.8 billion to 42.4 billion. Such estimates represent management's current and preliminary view, which are subject to change.

Exchange Rate

This announcement contains translation of certain Renminbi amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars were made at the exchange rate of RMB 6.7851 to US$ 1.00, the noon buying rate on June 30, 2026 as set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve Systems.

Use of Non-GAAP Financial Measures

The Company uses EBITDA, adjusted EBITDA, adjusted net income, adjusted net income attributable to ordinary shareholders, and adjusted basic and diluted earnings per American depositary share attributable to ordinary shareholders, each a non-GAAP financial measure, in evaluating ZTO's operating results and for financial and operational decision-making purposes.

Reconciliations of the Company's non-GAAP financial measures to its U.S. GAAP financial measures are shown in tables at the end of this earnings release, which provide more details about the non-GAAP financial measures.

The Company believes that such non-GAAP measures help identify underlying trends in the Company's business that could otherwise be distorted by the effect of the related expenses and gains that the Company includes in income from operations and net income, and provide useful information about its operating results, enhance the overall understanding of its past performance and future prospects and allow for greater visibility with respect to key metrics used by the Company's management in its financial and operational decision-making.

EBITDA, adjusted EBITDA, adjusted net income, adjusted net income attributable to ordinary shareholders and adjusted basic and diluted earnings per American depositary share attributable to ordinary shareholders should not be considered in isolation or construed as an alternative to net income or any other measure of performance or as an indicator of the Company's operating performance. Investors are encouraged to compare the historical non-GAAP financial measures to the most directly comparable GAAP measures. EBITDA, adjusted EBITDA, adjusted net income, adjusted net income attributable to ordinary shareholders and adjusted basic and diluted earnings per American depositary share attributable to ordinary shareholders presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to ZTO's data. ZTO encourages investors and others to review the Company's financial information in its entirety and not rely on a single financial measure.

Conference Call Information

ZTO's management team will host an earnings conference call at 8:30 PM U.S. Eastern Time on Tuesday, August 18, 2026 (8:30 AM Beijing Time on Wednesday, August 19, 2026).

Dial-in details for the earnings conference call are as follows:

Please dial in 15 minutes before the call is scheduled to begin and provide the passcode to join the call.

A replay of the conference call may be accessed by phone at the following numbers until August 24, 2026:

Additionally, a live and archived webcast of the conference call will be available at http://zto.investorroom.com.

About ZTO Express (Cayman) Inc.

ZTO Express (Cayman) Inc. (NYSE: ZTO and SEHK: 2057) ("ZTO" or the "Company") is a leading and fast-growing express delivery company in China. ZTO provides express delivery service as well as other value-added logistics services through its extensive and reliable nationwide network coverage in China.

ZTO operates a highly scalable network partner model, which the Company believes is best suited to support the significant growth of e-commerce in China. The Company leverages its network partners to provide pickup and last-mile delivery services, while controlling the mission-critical line-haul transportation and sorting network within the express delivery service value chain.

For more information, please visit http://zto.investorroom.com.

Safe Harbor Statement

This announcement contains statements that may constitute "forward-looking" statements pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "future," "intends," "plans," "believes," "estimates," "likely to," and other similar expressions. Among other things, the business outlook and quotations from management in this announcement contain forward-looking statements. ZTO may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC") and The Stock Exchange of Hong Kong Limited (the "HKEX"), in its interim and annual reports to shareholders, in announcements, circulars or other publications made on the website of the HKEX, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including but not limited to statements about ZTO's beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: risks relating to the development of the e-commerce and express delivery industries in China; its significant reliance on certain third-party e-commerce platforms; risks associated with its network partners and their employees and personnel; intense competition which could adversely affect the Company's results of operations and market share; any service disruption of the Company's sorting hubs or the outlets operated by its network partners or its technology system; ZTO's ability to build its brand and withstand negative publicity, or other favorable government policies. Further information regarding these and other risks is included in ZTO's filings with the SEC and the HKEX. All information provided in this announcement is as of the date of this announcement, and ZTO does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows:

For investor and media inquiries, please contact:
ZTO Express (Cayman) Inc.
Investor Relations
E-mail: [email protected]
Phone: +86 21 5980 4508

包裹量105億件，市場份額擴張至19.9%

調整後淨利潤增長50.3%至人民幣31億元

上海2026年8月18日 /美通社/ -- 中通快遞（開曼）有限公司（紐交所代碼：ZTO 及香港聯交所代號：2057），中國領先且快速成長的快遞公司（「中通」或「本公司」），今日公佈其截至 2026年6 月 30 日^[1]止第二季度的未經審計財務業績。本公司實現包裹量同比增長6.5%，同時保持優質服務及客戶滿意度。調整後淨利潤增加50.3%^[2]達人民幣31億元。經營活動產生的現金流量淨額為人民幣 46億元。

2026年第二季度財務摘要

• 收入為人民幣 14,549.9百萬元（2,144.4 百萬美元），較 2025年同期的人民幣 11,831.8 百萬元增長 23.0%。
• 毛利為人民幣 3,733.3百萬元（550.2 百萬美元），較 2025年同期的人民幣2,944.4百萬元增長26.8%。
• 淨利潤為人民幣3,077.6百萬元（453.6 百萬美元），較 2025年同期的人民幣1,964.6百萬元增長56.7%。
• 調整後息稅折攤前收益^[3]為人民幣 4,241.4百萬元（625.1百萬美元），較 2025年同期的人民幣 3,534.9百萬元增長20.0%。
• 調整後淨利潤為人民幣 3,086.1 百萬元（454.8 百萬美元），較 2025年同期的人民幣2,052.7 百萬元增長50.3%。
• 每股美國存託股（「ADS」^[4]）基本及攤薄淨收益分別為人民幣 3.99 元（0.59美元）及人民幣 3.78元（0.56美元），較 2025年同期的人民幣 2.42 元及人民幣 2.37 元分別增長64.9%及59.5%。
• 歸屬於普通股股東^[5]的調整後每股美國存託股基本及攤薄收益分別為人民幣 4.00 元（0.59美元）及人民幣 3.79 元（0.56美元），較 2025年同期的人民幣2.53元及人民幣2.48元分別增長 58.1%及52.8%。
• 經營活動產生的現金流量淨額為人民幣4,563.6百萬元（672.6百萬美元），而 2025年同期則為人民幣2,168.2百萬元。

2026年第二季度經營摘要

• 包裹量為 10,486 百萬件，較 2025年同期的 9,847百萬件增長 6.5%。
• 截至 2026年 6 月 30 日，攬件／派件網點數量為 31,000 餘個。
• 截至2026年 6 月 30 日，直接網絡合作夥伴數量約為 6,000 個。
• 截至2026年 6 月 30 日，自有幹線車輛數量為 10,000 餘輛。
• 截至 2026年 6 月 30 日，分揀中心之間的幹線路線數量為 3,600 餘條。
• 截至2026年 6 月 30 日，分揀中心數量為 92個，其中 87 個由本公司運營，5 個由本公司的網絡合作夥伴運營。

中通快遞創始人、董事長兼首席執行官賴梅松先生表示：「2026 年第二季度，中通繼續專注於提升服務品質和客戶體驗，持續優化運營效率，推動網絡政策的公平、透明。我們完成了業務量105億件，同比增長6.5%，高於行業平均增速2.3個百分點。調整後淨利潤達31億元人民幣。散件業務增速持續高於傳統電商件，這一結構性轉變在推動業務增長的同時，也有效提升了整體利潤水平。」

賴先生補充道：「中國快遞行業持續受益於監管的引導，行業利潤得到普遍改善，這標誌着行業發展重心從單純追求規模轉向價值驅動的『量質並舉』。中通『質量為先』的經營策略和穩定的業績表現，得益於我們領先行業的運營效率和公平導向的網絡治理。我們始終秉持着『同建共享』的理念，賦能並支持網絡合作夥伴和一線快遞小哥實現更好的經濟回報，同時為公司創造穩健的盈利能力。在監管政策的積極引導下，依托數字化能力的持續升級以及我們與網絡合作夥伴間深厚的信任與凝聚力，我們有充分的能力應對行業和經濟周期。」

中通快遞首席財務官顏惠萍女士表示：「今年第二季度，高價值大客戶業務佔比繼續提升，尤其是平台逆向業務快速增長帶來收入結構的持續優化。我們的核心快遞單票收入同比上升 15.5%。儘管油價波動，但通過數字化運營和精細化管理，單票分揀及運輸成本合計下降 2 分錢。銷售及管理費用（不含股權激勵費用）佔營業收入比重約為 3.8%，去年同期為 5.2%。本季度經營性現金流 46 億元人民幣，資本開支為 9.52 億元人民幣。」

顏女士補充道：「在當前市場增速有所放緩的環境下，中通長期秉持的可持續盈利增長的戰略依然行之有效。市場份額的穩步提升，得益於政府持續推動行業反內卷，同時也離不開公司對網絡穩定性的長期投入及其背後風險共擔、利益共享的分配機制。我們將繼續鞏固業務量的行業領先地位。同時，考慮到行業增長放緩，我們將全年業務量增速指引調整到 6%至 10%。」

收入總額為人民幣 14,549.9百萬元（2,144.4百萬美元），較2025年同期的人民幣 11,831.8  百萬元增長  23.0%。核心快遞業務收入較 2025 年同期增長 23.0%，這是包裹量增長 6.5%與單票收入上升15.5%綜合作用的結果。在核心快遞收入中, 由直銷機構產生的直客業務收入增長63.6%，主要受電子商務退貨包裹增加所帶動。貨運代理服務收入較 2025年同期增加21.1%。物料銷售收入（主要由銷售用於電子面單的熱敏紙組成）減少 1.7%。其他收入主要來自金融服務。

營業成本總額為人民幣10,816.6 百萬元（1,594.2 百萬美元），較去年同期的人民幣8,887.4 百萬元增長21.7%。

幹線運輸成本為人民幣 3,375.6 百萬元（497.5百萬美元），較去年同期的人民幣3,290.9百萬元增長2.6%。單票運輸成本減少 3.0%或 1 分，主要得益於更有效的路線規劃帶來規模經濟改善及裝載率提升，抵銷了柴油價格上漲的影響。

分揀中心運營成本為人民幣 2,505.8 百萬元（369.3百萬美元），較去年同期的人民幣2,414.8 百萬元增長 3.8%。該增加主要包括(i)人工相關成本增加人民幣84.5百萬元（12.5 百萬美元），經自動化帶來的效率提升所部分抵銷；及(ii)與自動化設施及設備升級相關的折舊及攤銷成本增加人民幣 14.8百萬元（2.2 百萬美元）。截至2026年6月30日，共782套自動化分揀設備投入使用，而截至2025年6月30日則為690套。

物料銷售成本為人民幣 145.8百萬元（21.5百萬美元），較去年同期的人民幣 151.2百萬元減少 3.6%。

其他成本為人民幣4,609.7 百萬元（679.4  百萬美元），較去年同期的人民幣 2,860.2百萬元增長 61.2%，主要由於向合作網點支付的與服務直客客戶相關的取件及派送成本增加人民幣1,620.4百萬元（238.8百萬美元），該等成本主要用於處理電子商務退件包裹。

毛利為人民幣 3,733.3百萬元（550.2百萬美元），較去年同期的人民幣2,944.4百萬元增長26.8%。毛利率上升至 25.7%，而去年同期則為 24.9%。

總經營費用為人民幣 505.3 百萬元（74.5百萬美元），而去年同期則為人民幣469.3 百萬元。

銷售、一般及行政費用為人民幣 556.7百萬元（82.0百萬美元），較去年同期的人民幣623.6百萬元減少 10.7%，主要由於去年同期確認了與融資應收款項相關的信用損失準備人民幣40.8百萬元（6.0百萬美元）。

其他經營收入淨額為人民幣 51.3百萬元（7.6百萬美元），去年同期則為人民幣154.3百萬元。其他經營收入主要包括(i)政府補助及稅費返還人民幣23.7 百萬元（3.5 百萬美元），及(ii)租金及其他收入人民幣27.6 百萬元（4.1 百萬美元）。

經營利潤為人民幣 3,227.9百萬元（475.7百萬美元），較去年同期的人民幣 2,475.1百萬元增加30.4%。經營利潤率增至22.2%，而去年同期則為20.9%。

利息收入為人民幣155.7  百萬元（22.9  百萬美元），而去年同期則為人民幣208.7 百萬元。

利息費用為人民幣 70.6 百萬元（10.4 百萬美元），而去年同期則為人民幣98.1百萬元。

金融工具公允價值變動的收益為人民幣 45.4 百萬元（6.7百萬美元），而去年同期則為損失人民幣3.6 百萬元。該等金融工具公允價值變動收益或損失由商業銀行根據市場預期的未來贖回價格報價。

所得稅費用為人民幣258.6百萬元（38.1 百萬美元），而去年同期則為人民幣575.5百萬元。整體所得稅率為7.7%，同比下降15.2 個百分點，主要由於本公司全資子公司上海中通吉網絡技術有限公司於獲認定為「重點軟件企業」後，其 2025納稅年度符合 10%的優惠稅率條件，從而收到人民幣344.3百萬元（50.7 百萬美元）的所得稅退稅。

淨利潤為人民幣3,077.6百萬元（453.6百萬美元），較去年同期的人民幣 1,964.6百萬元增長56.7%。

歸屬於普通股股東的每股美國存託股基本及攤薄收益分別為人民幣 3.99元（0.59美元）及人民幣3.78 元（0.56美元），而去年同期每股美國存託股的基本及攤薄收益分別為人民幣 2.42元及人民幣2.37元。

歸屬於普通股股東的調整後每股美國存託股基本及攤薄收益分別為人民幣4.00元（0.59美元）及人民幣3.79 元（0.56美元），而去年同期則分別為人民幣2.53 元及人民幣2.48 元。

調整後淨利潤為人民幣 3,086.1百萬元（454.8百萬美元），而去年同期則為人民幣2,052.7  百萬元。

息稅折攤前收益^[1]為人民幣4,231.3 百萬元（623.6百萬美元），而去年同期則為人民幣 3,446.8 百萬元。

調整後息稅折攤前收益為人民幣 4,241.4 百萬元（625.1百萬美元），而去年同期則為人民幣3,534.9  百萬元。

經營活動產生的現金流量淨額為人民幣4,563.6百萬元（672.6百萬美元），而去年同期則為人民幣2,168.2  百萬元。

委任新獨立董事

本公司董事會（「董事會」）宣佈，朱偉先生已獲委任為獨立董事，自2026年8月19日起生效。

朱先生擁有超過35年的管理諮詢、投資銀行、私募股權投資及大型企業管理經驗。2026年4月至今，朱先生擔任上海雲勵科技有限公司及其AI附屬公司董事及顧問。2024年6月至2026年2月，朱先生擔任安邁諮詢北亞區聯席主席。2018年至2021年，朱先生擔任埃森哲(Accenture)大中華區主席，並於2020年獲委任為埃森哲全球管理委員會成員。此前，朱先生於2009年至2017年擔任渣打銀行直接投資業務全球聯席總裁，2008年至2009年擔任CVC資本亞太高級董事總經理，2005年至2008年擔任高盛高華董事總經理，2004年至2005年擔任羅蘭貝格管理諮詢公司高級合夥人兼大中國區總裁，2001年至2003年擔任科爾尼管理咨詢公司大中華區總裁。朱先生自2021年9月起擔任上海外服控股集團股份有限公司獨立董事。朱先生於1986年獲得喬治城大學外交學學士學位，並於1992年獲得芝加哥大學工商管理碩士學位。

股東回報更新

誠如於2026年3月所披露，董事會已批准一項經完善的回報機制，據此，本公司致力於實現總年度股東回報比率不低於上一財政年度經調整淨收入的50%，當中包括現金股息及股份購回。

截至第二季度末，本公司於2026年已累計購回合共31,788,692股A類普通股，代價為740百萬美元（包括回購佣金），相當於其2025年經調整淨收入的52%。因此，董事會不建議派發2026年上半年的中期股息。

於2026年3月，董事會亦批准一項新股份購回計劃（「新計劃」），授權於2026年3月20日至2028年3月20日止為期24個月的期間內購回最多達15.0億美元的股份。截至2026年第二季度末，本公司已根據新計劃回購合共6,161,216股美國存託股，代價為138百萬美元（包括回購佣金），授權項下尚餘13.60億美元的額度。

前景展望

基於當前市場及經營狀況，本公司修訂此前公佈的年度指引。2026年包裹量預計同比增長6.0%至10.0%，即包裹量介乎408億至424億件。該等估計為管理層當前及初步的看法，可能作出變動。

匯率

僅為方便讀者閱讀，本公告將若干人民幣金額按指定匯率轉換為美元。除非另有所指，所有人民幣兌換為美元的換算乃按人民幣6.7851元兌 1.00 美元的匯率作出（即美國聯邦儲備系統管理委員會 H.10 統計數據所載 2026年6月 30 日之中午買入匯率）。

採用非公認會計準則財務指標

本公司使用息稅折攤前收益、調整後息稅折攤前收益、調整後淨利潤、歸屬於普通股股東的調整後淨利潤及歸屬於普通股股東的調整後每股美國存託股基本及攤薄收益（均為非公認會計準則財務指標）來評估中通的經營業績，並用於財務及經營決策。

本公司的非公認會計準則財務指標與其美國公認會計準則財務指標之間的調節表列示於本盈利發佈末的表格，該表格提供有關非公認會計準則財務指標的更多詳情。

本公司認為，該等非公認會計準則指標有助於識別本公司業務的基本趨勢，避免其因本公司在經營利潤及淨利潤中計入的相關費用和利得而失真，並提供了關於其經營業績的有用資料，增強對其過往表現及未來前景的整體理解，並有助於更清晰地了解本公司管理層在財務和運營決策中所使用的核心指標。

息稅折攤前收益、調整後息稅折攤前收益、調整後淨利潤、歸屬於普通股股東的調整後淨利潤及歸屬於普通股股東的調整後每股美國存託股基本及攤薄收益不應獨立於淨利潤或其他業績指標考慮，亦不可詮釋為淨利潤或其他業績指標的替代項目，或詮釋為本公司經營表現的指標。中通鼓勵投資者將過往的非公認會計準則財務指標與最直接可比的公認會計準則指標進行比較。本文所列的息稅折攤前收益、調整後息稅折攤前收益、調整後淨利潤、歸屬於普通股股東的調整後淨利潤及歸屬於普通股股東的調整後每股美國存託股基本及攤薄收益可能無法與其他公司列示的名稱類似的指標相比較。其他公司可能會以不同的方式計算類似名稱的指標，從而限制了其作為中通數據的比較指標的有用性。中通鼓勵投資者及其他人士全面審閱本公司的財務資料，而非依賴單一的財務指標。

電話會議資料

中通的管理團隊將於美國東部時間 2026年 8 月 18 日（星期二）下午八時三十分（北京時間 2026年 8 月 19 日（星期三）上午八時三十分）舉行業績電話會議。

業績電話會議的撥號詳情如下：

請於通話預定開始前 15 分鐘撥號，並提供密碼以加入通話。

電話會議的回放將可於 2026年 8 月 24 日前通過致電以下號碼收聽：

此外，電話會議的網上直播及錄音將可於 http://zto.investorroom.com 收聽。

關於中通快遞（開曼）有限公司

中通快遞（開曼）有限公司（紐交所代碼：ZTO 及香港聯交所代號：2057）（「中通」或「本公司」）是中國行業領先且快速成長的快遞公司。中通通過其在中國廣泛且可靠的全國性覆蓋網絡提供快遞服務以及其他增值物流服務。

中通運營高度可擴展的網絡合作夥伴模式，本公司認為，該模式最適於支持中國電子商務的高速增長。本公司利用其網絡合作夥伴提供攬件和末端派送服務，同時在快遞服務價值鏈內提供關鍵的幹線運輸服務和分揀網絡。

有關更多資料，請訪問 http://zto.investorroom.com。

安全港聲明

本公告載有根據 1995 年《美國私人證券訴訟改革法》的「安全港」條文可能構成「前瞻性」聲明的陳述。該等前瞻性陳述可從詞彙如「將」、 「預期」、「預計」、「旨在」、「未來」、「擬」、「計劃」、「相信」、「估計」、「可能」或類似陳述加以識別。當中前景展望及管理層在本公告的引述均包含前瞻性陳述。中通亦可能在其向美國證券交易委員會（「美國證交會」）及香港聯合交易所有限公司（「香港聯交所」）提交的定期報告、向股東提交的中期及年度報告、於香港聯交所網站上發佈的公告、通函或其他刊物、新聞稿及其他書面材料以及其高級職員、董事或僱員向第三方作出的口頭陳述中作出書面或口頭前瞻性陳述。非歷史事實的陳述，包括但不限於有關中通的信念、計劃及期望的陳述，均屬於前瞻性陳述。前瞻性陳述涉及固有風險及不確定因素。許多因素可導致實際結果與任何前瞻性陳述中包含的結果有重大差異，包括但不限於以下各項：有關中國電子商務及快遞行業發展的風險；其對若干第三方電子商務平台的重大依賴；與其網絡合作夥伴及其僱員及人員相關的風險；可能對本公司經營業績及市場份額造成不利影響的激烈競爭；本公司分揀中心或其網絡合作夥伴運營的網點或其技術系統遭受任何服務中斷；中通建立品牌及承受負面報道的能力或其他有利的政府政策。有關此等及其他風險的進一步資料載於中通向美國證交會及香港聯交所提交的文件中。本公告中提供的所有資料均截至本公告日期，除適用法律要求外，中通不承擔更新任何前瞻性陳述的義務。